Always a day late and a dollar short. And Ippolito is still fat.
You’re not going to believe what happened to Novavax
Novavax, whose potent Covid-19 vaccine all but missed out on the peak of the pandemic, is staking its future on selling booster doses into a shrinking market. But the first step of the process — winning FDA approval for an updated vaccine — didn’t quite go to plan.
As STAT’s Helen Branswell and Matthew Herper report, the FDA approved reformulated vaccines from Moderna and partners Pfizer and BioNTech, based on data that they work against novel variants of the virus. Missing from the announcement was Novavax, whose booster was also up for approval. The company “is currently responding to the FDA’s requests to facilitate final review, and timing is ultimately at the discretion of the FDA,” Novavax said in a statement, adding that it still expects its booster to be “widely available this September for consumers.”
The company’s long-suffering shareholders can be forgiven for feeling like they’ve heard this one before. Throughout 2021, Novavax repeatedly made and broke promises to speedily commercialize what was an unquestionably effective vaccine. Now, facing the legitimate threat of bankruptcy, Novavax needs to capitalize on the market for boosters, and it has already missed one milestone.
Read more.
You’re not going to believe what happened to Novavax
Novavax, whose potent Covid-19 vaccine all but missed out on the peak of the pandemic, is staking its future on selling booster doses into a shrinking market. But the first step of the process — winning FDA approval for an updated vaccine — didn’t quite go to plan.
As STAT’s Helen Branswell and Matthew Herper report, the FDA approved reformulated vaccines from Moderna and partners Pfizer and BioNTech, based on data that they work against novel variants of the virus. Missing from the announcement was Novavax, whose booster was also up for approval. The company “is currently responding to the FDA’s requests to facilitate final review, and timing is ultimately at the discretion of the FDA,” Novavax said in a statement, adding that it still expects its booster to be “widely available this September for consumers.”
The company’s long-suffering shareholders can be forgiven for feeling like they’ve heard this one before. Throughout 2021, Novavax repeatedly made and broke promises to speedily commercialize what was an unquestionably effective vaccine. Now, facing the legitimate threat of bankruptcy, Novavax needs to capitalize on the market for boosters, and it has already missed one milestone.
Read more.